Drugs / Exenatide extended-release (ER)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02104739 | Apr 2014 → Mar 2017 | obesity disorder, prediabetes syndrome | The University of Texas Health Science Center, Houston | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Exenatide extended-release (ER) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02104739 ↗ |
| Action | Activate | “exenatide (GLP-1 agonist)” NCT02104739 ↗ |
| Route | Subcutaneous | “Subcutaneous injection (2mg) weekly for 6 weeks” NCT02104739 ↗ |